Lilly
Executive Summary
Licenses Cytogen's proprietary monoclonal antibody-based technology for the site-specific delivery of vinca alkaloid compounds and other cancer therapies patented by Lilly in return for an unspecified licensing fee, an equity investment and royalty payments. Lilly will be responsible for clinicals and seeking FDA approval. Firms have completed animal testing of possible product formulations. Agreement will complement monoclonal antibody research activities at Lilly's Hybritech subsidiary.